The Zacks Analyst Blog Highlights: Medtronic, Covidien, Mylan, Actavis and Jazz Pharmaceuticals - News, Weather and Sports for Lincoln, NE; KLKNTV.com

The Zacks Analyst Blog Highlights: Medtronic, Covidien, Mylan, Actavis and Jazz Pharmaceuticals

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Zacks Investment Research, Inc.

CHICAGO, Aug. 1, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Medtronic, Inc. (NYSE:MDT-Free Report), Covidien plc (NYSE:COV-Free Report), Mylan, Inc. (Nasdaq:MYL-Free Report), Actavis plc (NYSE:ACT-Free Report) and Jazz Pharmaceuticals (Nasdaq:JAZZ-Free Report).

Zacks Investment Research, Inc., www.zacks.com

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Thursday's Analyst Blog:

Tax Inversion: The Boon and the Bane

The US federal government may be threatened to lose billions of dollars in revenues. A joint congressional committee on taxation estimates the U.S. Treasury may lose $19.5 billion over the next decade. On the other hand, the corporate houses, which may include some of your favorite stocks, are strategically well placed to save those billion bucks. The common reason for these is Tax inversion. 

Simply put, this latest trend is US corporate houses acquiring offshore companies in nations that offer a lower tax rates. By acquiring the foreign companies, these US firms are shifting their legal homes and thereby chopping the tax bills. 

The global merger & acquisition (M&A) activity clocked a seven-year high. Recurrent foreign acquisitions by U.S. companies indicate that tax inversion is one of the major reasons behind the spike. The tax rate is the highest in the US and thus it is logical for the US firms to find alternative sources whereby they can limit their tax burden. 

No matter what it costs to the exchequer, trimming the tax burden will eventually help the US firms have more cash in their pocket. This additional cash along with advantages like boosting a product portfolio or adding skilled workforce through acquisitions should help these firms do better. Eventually, this should get reflected in their stock prices as well.  

What Is Tax Inversion?

Medtronic, Inc.'s (NYSE:MDT-Free Report) $42.9 billion acquisition of its Irish competitor in surgical technologies and global healthcare major Covidien plc (NYSE:COV-Free Report) is a good example of the tax inversion process. The deal was an effort to offset the impact of high U.S. corporate tax rate by shifting Medtronic's tax base overseas.

A tax inversion involves the acquisition of a foreign company and subsequently adopting its home country's domicile. Alternatively, the combined entity can create a holding company in a country where tax rate is lower.

Healthcare Sector Taps Most of the Opportunity

We note that the trend of tax inversion has been mostly prevalent in the healthcare sector. Medical devices and pharma companies are rapidly buying foreign competitors. It is usually easier for a large corporation to purchase small companies than to develop new drugs indigenously. Also, the market for drugs is truly global. Thus the advantages are huge in addition to offloading the tax burden.

Many large US pharma companies already have considerable international revenue base. Tax inversion will further increase their international presence. A strong European pharma sector also makes for several potential targets.

Apart from Medtronic, Mylan, Inc. (Nasdaq:MYL-Free Report), Actavis plc (NYSE:ACT-Free Report) and Jazz Pharmaceuticals (Nasdaq:JAZZ-Free Report) are among the other players in the pharma space reaping the benefits. (Read: Pharma, Biotech M&As Heat Up: Tax Inversion in Focus)

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on MDT - FREE

Get the full Report on COV - FREE

Get the full Report on MYL - FREE

Get the full Report on ACT - FREE

Get the full Report on JAZZ - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KLKN. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.